Overlooking Subvisible Particles in Therapeutic Protein Products: Gaps That May Compromise Product Quality
Top Cited Papers
Open Access
- 1 April 2009
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 98 (4) , 1201-1205
- https://doi.org/10.1002/jps.21530
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Stabilization of a hydrophobic recombinant cytokine by human serum albuminJournal of Pharmaceutical Sciences, 2007
- Urgent inhibitor issues: targets for expanded researchHaemophilia, 2006
- Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitorsBritish Journal of Haematology, 2006
- Immunogenicity of biopharmaceuticalsNephrology Dialysis Transplantation, 2006
- Protein aggregation and bioprocessingThe AAPS Journal, 2006
- Effects of protein aggregates: An immunologic perspectiveThe AAPS Journal, 2006
- Pathogen recognition and development of particulate vaccines: Does size matter?Methods, 2006
- Structural Characterization and Immunogenicity in Wild-Type and Immune Tolerant Mice of Degraded Recombinant Human Interferon Alpha2bPharmaceutical Research, 2005
- Heterogeneous Nucleation-Controlled Particulate Formation of Recombinant Human Platelet-Activating Factor Acetylhydrolase in Pharmaceutical FormulationJournal of Pharmaceutical Sciences, 2005
- Acute and Long-Term Stability Studies of Deoxy Hemoglobin and Characterization of Ascorbate-Induced ModificationsJournal of Pharmaceutical Sciences, 1999